Designing of Complex Multi-epitope Peptide Vaccine Based on Omps of Klebsiella pneumoniae: An In Silico Approach

Farhadi, Tayebeh; Nezafat, Navid; Ghasemi, Younes; Karimi, Zeinab; Hemmati, Shiva; Erfani, Nasrollah

doi:10.1007/s10989-015-9461-0

Cited by 42 publications

(21 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacterial genomics and proteomics analysis indeed help researchers analyze proteins, short domains, and pathogenic epitopes that provide high immunogenicity and high antigenicity for multimeric vaccine development 25 . Therefore, immunoproteomics should be applied as a preliminary process to screen antigenic proteins and minimize potential candidates for vaccine development 21 .…”

Section: Discussionmentioning

confidence: 99%

“…To achieve a high level of protein expression in Nile tilapia, codon optimization was conducted to improve the transcription and translation capability by removing all possible cis-acting sequence motifs, which may have a negative impact on protein expression. Both proteins had a CAI > 0.8 and a codon with frequent distribution (CFD) > 30%, which are acceptable for high expression in the target organism 18,21 . The GC content of 45F2 and 42E2 was optimized between 30-70% and had a suitable thermodynamic ensemble free energy, which allowed RNA folding and thermodynamic stability 35,36 .…”

Section: Discussionmentioning

confidence: 99%

“…Each individual epitope in a chimeric polypeptide vaccine may provide a high efficacy vaccine by inducing and enhancing robust and specific humoral responses in addition to other cellular responses, particularly opsonization activity 20 . Moreover, proper linkers have been considered to minimize steric hindrance of each chimeric epitope and enhance epitope presentation to the host immune system 21 .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Pumchan

Krobthong

Roytrakul

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Streptococcus agalactiae is a causative agent of streptococcosis disease in various fish species, includingnile tilapia (Oreochromis niloticus Linn.). Vaccination is an effective disease prevention and control method, but limitations remain for protecting against catastrophic mortality of fish infected with different strains of streptococci. Immunoproteomics analysis of S. agalactiae was used to identify antigenic proteins and construct a chimeric multiepitope vaccine. Epitopes from five antigenic proteins were shuffled in five helices of a flavodoxin backbone, and in silico analysis predicted a suitable RnA and protein structure for protein expression. 45F2 and 42E2 were identified as the best candidates for a chimeric multiepitope vaccine. Recombinant plasmids were constructed to produce a recombinant protein vaccine and DNA vaccine system. Overexpressed proteins were determined to be 30 kDa and 25 kDa in the E. coli and TK1 systems, respectively. The efficacy of the chimeric multiepitope construct as a recombinant protein vaccine and DnA vaccine was evaluated in nile tilapia, followed by S. agalactiae challenge at 1 × 10 7 cfU/mL. Relative percentage survival (RpS) and cumulative mortality were recorded at approximately 57-76% and 17-30%, respectively. These chimeric multiepitope vaccines should be applied in streptococcosis disease control and developed into a multivalent vaccine to control multiple diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Pumchan

Krobthong

Roytrakul

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Hence, these vaccines are considered efficient Toth, 2011, 2014). Based on the mentioned merits, many researchers, including our team, have worked extensively on the development of these types of vaccines (Farhadi et al, 2015;Hajighahramani et al, 2017;Mahmoodi et al, 2016;Nezafat et al, 2017;Nezafat et al, 2014;Nezafat et al, 2016;Shahbazi et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Harnessing self-assembled peptide nanoparticles in epitope vaccine design

Negahdaripour

Golkar

Hajighahramani

et al. 2017

Biotechnology Advances

Self Cite

View full text Add to dashboard Cite

Vaccination has been one of the most successful breakthroughs in medical history. In recent years, epitope-based subunit vaccines have been introduced as a safer alternative to traditional vaccines. However, they suffer from limited immunogenicity. Nanotechnology has shown value in solving this issue. Different kinds of nanovaccines have been employed, among which virus-like nanoparticles (VLPs) and self-assembled peptide nanoparticles (SAPNs) seem very promising. Recently, SAPNs have attracted special interest due to their unique properties, including molecular specificity, biodegradability, and biocompatibility. They also resemble pathogens in terms of their size. Their multivalency allows an orderly repetitive display of antigens on their surface, which induces a stronger immune response than single immunogens. In vaccine design, SAPN self-adjuvanticity is regarded an outstanding advantage, since the use of toxic adjuvants is no longer required. SAPNs are usually composed of helical or β-sheet secondary structures and are tailored from natural peptides or de novo structures. Flexibility in subunit selection opens the door to a wide variety of molecules with different characteristics. SAPN engineering is an emerging area, and more novel structures are expected to be generated in the future, particularly with the rapid progress in related computational tools. The aim of this review is to provide a state-of-the-art overview of self-assembled peptide nanoparticles and their use in vaccine design in recent studies. Additionally, principles for their design and the application of computational approaches to vaccine design are summarized.

show abstract

“…In general, the majority of epitope-based vaccines can cause induction of cellular or/and humoral immunity as well as offer a safer and more easy-produced alternative for the prevention of diseases; however, the low immunogenicity is the main disadvantage of such types of vaccines. For solving this problem, several methods have been used to enhance the immunogenicity epitopes vaccines, like prescribing the multiple doses of vaccine, adding immunostimulatory agents such an adjuvant to the vaccine [9], and the recent strategy is applying self-assembled peptide motif including betasheets or coiled-coil structures in the epitope vaccine [10]. Besides above-mentioned strategies, incorporating universal T-helper epitopes like diphtheria toxoids (DTD) into vaccine can enhance vaccine efficacy.…”

Section: Introductionmentioning

confidence: 99%

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Dorosti

Eslami

Nezafat

et al. 2019

Molecular and Cellular Probes

Self Cite

View full text Add to dashboard Cite

A B S T R A C TStreptococcus pneumoniae is the main cause of diseases such as meningitis, pneumoniae and sepsis, especially in children and old people. Due to costly antibiotic treatment, and increasing resistance of pneumococcus, developing high-efficient protective vaccine against this pathogen is an urgent need. Although the pneumoniae polysaccharide vaccine (PPV) and pneumonia conjugate vaccines (PCV) are the efficient pneumococcal vaccine in children and adult groups, but the serotype replacement of S. pneumoniae strains causes the reduction in efficacy of such vaccines. For overcoming the aforesaid drawbacks epitope-based vaccines are introduced as the relevant alternative. In our previous research, the epitope vaccine was designed based on immunodominant epitopes from PspA, CbpA antigens as cellular stimulants and PhtD, PiuA as humoral stimulants. Because the low immunogenicity is the main disadvantage of epitope vaccine, in the current study, we applied coiled-coil selfassembled structures for developing our vaccine. Recently, self-assembled peptide nanoparticles (SAPNs) have gained much attention in the field of vaccine development due to their multivalency, self-adjuvanticity, biocompatibility, and size similarity to pathogen. In this regard, the final designed vaccine is comprised of cytotoxic T lymphocytes (CTL) epitopes from PspA and CbpA, helper T lymphocytes (HTL) epitopes from PhtD and PiuA, the pentamer and trimmer oligomeric domains form 5-stranded and 3-stranded coiled-coils as self-assembled scaffold, Diphtheria toxoids (DTD) as a universal T-helper, which fused to each other with appropriate linkers. The four different arrangements based on the order of above-mentioned compartments were constructed, and each of them were modeled, and validated to find the 3D structure. The structural, physicochemical, and immunoinformatics analyses of final vaccine construct represented that our vaccine could stimulate potent immune response against S. pneumoniae; however, the potency of that should be approved via various in vivo and in vitro immunological tests.

show abstract

Designing of Complex Multi-epitope Peptide Vaccine Based on Omps of Klebsiella pneumoniae: An In Silico Approach

Cited by 42 publications

References 69 publications

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.)

Harnessing self-assembled peptide nanoparticles in epitope vaccine design

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Contact Info

Product

Resources

About